Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

TGTX

TG Therapeutics Inc

Jun 10 • 04:00PM ET

46.62

+3.25 7.49 %

Healthcare • Biotechnology • USA • Mid • NASD

Jun 09, 7:35 AMTG Therapeutics reports positive topline Phase 1 data for subcutaneous BRIUMVI in myasthenia gravis

Peers: INCY BMRN ACAD AXSM MDGL KRYS PTGX RYTM VKTX NBIX

| Held by: IJR VTI IWM XBI VB VBK SPSM IJT VXF IWO

Scroll to Statements

Index	RUT	P/E	16.25	EPS (ttm)	2.87	Insider Own	7.16%	Shs Outstand	153.09M	Perf Week	16.23%
Market Cap	7.14B	Forward P/E	18.41	EPS next Y	2.53	Insider Trans	0.00%	Shs Float	142.12M	Perf Month	8.07%
Enterprise Value	7.38B	PEG	5.14	EPS next Q	0.36	Inst Own	69.14%	Short Float	19.83%	Perf Quarter	66.20%
Income	461.90M	P/S	10.19	EPS this Y	-50.18%	Inst Trans	0.84%	Short Ratio	13.53	Perf Half Y	51.22%
Sales	700.35M	P/B	12.24	EPS next Y	83.51%	ROA	42.27%	Short Interest	28.18M	Perf YTD	56.39%
Book/sh	3.81	P/C	13.87	EPS next 5Y	3.58%	ROE	112.60%	52W High	44.65 4.41%	Perf Year	18.23%
Cash/sh	3.36	P/FCF	-	EPS past 3/5Y	- -	ROIC	34.60%	52W Low	25.28 84.41%	Perf 3Y	69.77%
Dividend Est.	-	EV/EBITDA	48.83	Sales past 3/5Y	504.86% 426.73%	Gross Margin	83.05%	Volatility	6.48% 4.30%	Perf 5Y	22.78%
Dividend TTM	-	EV/Sales	10.53	EPS Y/Y TTM	1079.73%	Oper. Margin	21.35%	ATR (14)	2.08	Perf 10Y	551.12%
Dividend Ex-Date	-	Quick Ratio	5.12	Sales Y/Y TTM	81.26%	Profit Margin	65.95%	RSI (14)	73.76	Recom	1.62
Dividend Gr. 3/5Y	- -	Current Ratio	5.81	EPS Q/Q	297.43%	SMA20	16.37%	Beta	1.62	Target Price	48.00
Payout	0.00%	Debt/Eq	1.29	Sales Q/Q	69.56%	SMA50	23.63%	Rel Volume	2.45	Prev Close	43.37
Employees	399	LT Debt/Eq	1.29	Earnings	May 06 BMO	SMA200	41.27%	Avg Volume	2.08M	Price	46.62
IPO	Dec 14, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	-56.44% 2.29%	Trades		Volume	5,110,829	Change	7.49%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-06-25	Resumed	H.C. Wainwright	Buy	$60
Jul-10-25	Resumed	Goldman	Neutral	$37
Oct-29-24	Initiated	TD Cowen	Buy	$50
Aug-02-23	Upgrade	Goldman	Sell → Neutral	$16 → $12
Jun-26-23	Resumed	Jefferies	Buy	$55 → $40
May-20-22	Initiated	BofA Securities	Underperform	$5
Feb-23-22	Reiterated	B. Riley Securities	Buy	$49 → $35
Nov-15-21	Downgrade	Goldman	Neutral → Sell	$33 → $26
Apr-20-21	Initiated	Goldman	Neutral	$50
Apr-19-21	Reiterated	H.C. Wainwright	Buy	$79 → $89
Sep-01-20	Initiated	JP Morgan	Overweight	$38
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$32 → $38
Jun-05-20	Initiated	Evercore ISI	Outperform	$60
Jan-17-20	Reiterated	H.C. Wainwright	Buy	$20 → $24
Nov-27-19	Resumed	B. Riley FBR	Buy	$12
Feb-06-19	Resumed	Jefferies	Buy	$8
Sep-25-18	Downgrade	Raymond James	Strong Buy → Outperform
Mar-09-18	Reiterated	B. Riley FBR, Inc.	Buy	$21.50 → $27
Dec-01-17	Resumed	B. Riley FBR, Inc.	Buy	$21.50
Nov-14-17	Resumed	H.C. Wainwright	Buy	$33

Show Previous Ratings

Jun-10-26 12:57PM	Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Four-Year High (Investor's Business Daily) +7.49%
Jun-09-26 05:03PM	Dow Jones Futures: Market Whipsaws On AI Fears, Trump's Iran Comments; CPI Inflation On Tap (Investor's Business Daily) +5.91%
04:34PM	TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease (Stocktwits)
07:30AM	TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial (GlobeNewswire)
Jun-03-26 04:48PM	TG Therapeutics Flashes An Early Buy Signal - What Drove The Bullish Jump (Investor's Business Daily) +9.47%
12:43PM	Loading…
12:43PM	TGTX Stock Applies Brakes On 5-Session Losing Streak Retail Eyes Multi-Billion Sales As At-Home Multiple Sclerosis Treatment Gets Boost (Stocktwits)
07:30AM	TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI (ublituximab-xiiy) (GlobeNewswire)
Jun-02-26 07:30AM	TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference (GlobeNewswire)
Jun-01-26 07:30AM	TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology (GlobeNewswire)
May-28-26 07:30AM	TG Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-26 07:30AM	TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial (GlobeNewswire)
May-26-26 07:30AM	TG Therapeutics Announces Data Presentations for BRIUMVI at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting (GlobeNewswire)
May-21-26 12:24PM	Multiple Sclerosis-Focused Biotech Quadruples Its Profit, Raises Sales Forecast (Investor's Business Daily)
May-11-26 02:00PM	Historic Signal Says This Biotech Outperforms (Schaeffer's Research)
May-06-26 04:57PM	TG Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby) +16.26%
07:21AM	Loading…
07:21AM	TG Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
May-05-26 07:01AM	Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Apr-30-26 07:30AM	TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Apr-22-26 07:30AM	TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire) +5.60%
Apr-16-26 05:52AM	TG Therapeutics concludes enrolment in Phase III Briumvi trial (Clinical Trials Arena)
Apr-15-26 07:30AM	TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI (GlobeNewswire)
Mar-19-26 07:30AM	TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million (GlobeNewswire)
Mar-12-26 07:00AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-10-26 08:03AM	BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) (Insider Monkey)
Mar-09-26 07:30AM	Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI in People with Highly Active Relapsing Multiple Sclerosis (GlobeNewswire)
Mar-08-26 06:25AM	Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings (Insider Monkey)
Mar-06-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire)
Mar-02-26 07:01AM	Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
Mar-01-26 04:27AM	TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 (Insider Monkey)
12:08PM	Loading…
Feb-27-26 12:08PM	TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line (Zacks)
08:45AM	TG Therapeutics Q4 Earnings Call Highlights (MarketBeat)
Feb-26-26 04:11PM	TG Therapeutics Inc (TGTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
09:55AM	TG Therapeutics (TGTX) Misses Q4 Earnings Estimates (Zacks)
08:30AM	TG Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
07:12AM	TG Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Feb-25-26 12:15PM	Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-23-26 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:30AM	TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update (GlobeNewswire)
Feb-17-26 07:30AM	Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis (GlobeNewswire)
Feb-11-26 03:14PM	Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance (Insider Monkey)
Feb-08-26 04:17PM	TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis (GlobeNewswire)
Feb-07-26 03:33AM	TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan (Insider Monkey)
Feb-06-26 07:30AM	TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Jan-27-26 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum (GlobeNewswire)
Jan-15-26 10:31AM	These under-the-radar stocks combine fast growth with big upside potential (MarketWatch)
Jan-14-26 04:39PM	Stock Indexes Settle Lower on Tech Weakness (Barchart) +5.99%
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
09:45AM	Stocks to Watch Wednesday: Netflix, Bank of America, Wells Fargo (The Wall Street Journal)
09:25AM	Why TG Therapeutics Stock Is Moving Today (Benzinga)
05:03AM	Stock Market Today: Dow Jones, Nasdaq 100 Futures Tumble Ahead Of Supreme Court Ruling On Trump's Tariffs-Wells Fargo, BP, WeRide In Focus (Benzinga)
Jan-13-26 05:05PM	TG Therapeutics Stock Climbs After The Bell: Here's Why (Benzinga)
04:25PM	TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones (GlobeNewswire)
Jan-07-26 07:30AM	TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-25 08:32AM	Is the Options Market Predicting a Spike in TG Therapeutics Stock? (Zacks)
Nov-28-25 07:30AM	TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-19-25 08:30AM	TG Therapeutics Makes 2025 Deloitte Technology Fast 500 List of America's Fastest-Growing Companies (GlobeNewswire)
Nov-10-25 04:00PM	TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) -6.02%
12:01PM	TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results (Investor's Business Daily)
Nov-05-25 09:45AM	Why TG Therapeutics (TGTX) is a Top Growth Stock for the Long-Term (Zacks)
Nov-04-25 10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
Nov-03-25 04:25PM	Highly Watched TG Therapeutics Smashes Profit Views But There's A Caveat (Investor's Business Daily)
04:00PM	TG Therapeutics Inc (TGTX) Q3 2025 Earnings Call Highlights: Record Revenue Surge and Strategic ... (GuruFocus.com)
08:53AM	Highly Watched TG Therapeutics Smashes Profit Views - With A Caveat (Investor's Business Daily)
07:09AM	TG Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Oct-31-25 07:30AM	TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Oct-28-25 05:55PM	Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Earnings Preview: Amgen (AMGN) Q3 Earnings Expected to Decline (Zacks)
07:30AM	TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
Sep-25-25 06:24AM	Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? (Zacks)
Sep-24-25 09:10AM	New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment (GlobeNewswire)
Sep-10-25 07:30AM	TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting (GlobeNewswire)
Sep-08-25 07:30AM	TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment (GlobeNewswire)
Sep-04-25 07:30AM	TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Sep-03-25 12:40PM	TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback (Benzinga) +6.66%
11:30AM	Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report? (Zacks)
07:30AM	TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program (GlobeNewswire)
Aug-28-25 08:00AM	TG Therapeutics to Participate in the Cantor Global Healthcare Conference (GlobeNewswire)
Aug-05-25 01:06PM	TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance (Insider Monkey)
12:12PM	TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line (Zacks)
09:30AM	Company News for Aug 5, 2025 (Zacks)
03:00AM	TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Aug-04-25 01:14PM	Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide (Benzinga) -17.99%
11:29AM	Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook (Investor's Business Daily)
08:10AM	TG Therapeutics (TGTX) Misses Q2 Earnings Estimates (Zacks)
07:04AM	TG Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance (GlobeNewswire)
Jul-30-25 10:00AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:30AM	TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Jul-29-25 10:24AM	Analysts Hike Profit Targets On This Gold Stock, Defense Name (Investor's Business Daily)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
Jul-02-25 12:05PM	Jim Cramer on TG Therapeutics: "You Should Buy the Stock" (Insider Monkey)
Jun-30-25 09:22PM	Lightning Round: Buy anything uranium, says Jim Cramer (CNBC TV)
Jun-16-25 09:47AM	Are Options Traders Betting on a Big Move in TG Therapeutics Stock? (Zacks)

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

J.D.Mr. Michael S. Weiss Esq.

CFOMr. Sean A. Power CPA

Senior Vice President of Corporate CommunicationsMs. Jenna Bosco

Chief Commercialization OfficerMr. Adam Waldman

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Echelard Yann	Director	Nov 24 '25	Sale	32.57	5,000	162,850	223,816	Nov 25 05:31 PM
Echelard Yann	Director	Nov 24 '25	Proposed Sale	32.57	5,000	162,850		Nov 24 04:04 PM
Lonial Sagar	Director	Sep 11 '25	Sale	32.24	20,852	672,268	94,061	Sep 12 04:42 PM
Lonial Sagar	Director	Sep 11 '25	Proposed Sale	32.24	20,852	672,233		Sep 11 04:55 PM
Echelard Yann	Director	Jun 13 '25	Sale	36.94	10,000	369,400	228,816	Jun 16 05:47 PM
Echelard Yann	Director	Jun 13 '25	Proposed Sale	36.93	10,000	369,348		Jun 13 12:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TGTX

TG Therapeutics Inc

Upgrade your Finviz experience